HGH vs Proviron
FDA Approved vs Well Studied
synergistic Mechanism-based · 60% Proviron helps manage estrogen conversion from HGH. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
HGH Proviron
Weight 22,124 Da 304.47 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) ~12 hours
Chain 191 amino acids —
Type Single-chain polypeptide with two disulfide bridges DHT derivative (C20H32O2)
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Proviron
01 Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
02 Improved mood, motivation, confidence, and overall sense of well-being
03 Significant enhancement of libido and sexual function
04 Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
05 Harder, drier, more defined physical appearance without water retention
06 Minimal hepatotoxicity due to absence of 17-alpha alkylation
07 May improve sperm quality at low doses in subfertile men
08 Rapid onset of subjective well-being effects (often within days)
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Proviron
25-75 mg/day / 1-3x per day (oral)
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Proviron
Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
Oily skin and increased sebum production
Mild HDL cholesterol suppression with extended use
Increased body hair growth
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Prostate cancer (active or history of androgen-sensitive prostate cancer)
Severe liver impairment (though hepatotoxicity risk is minimal)
Breast cancer in males
Hypersensitivity to mesterolone or any excipients
Women who are pregnant or may become pregnant (androgenic effects on fetus)
Research Evidence
HGH Proviron
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.